- Home
- TPST vs ASBP Comparison
TPST vs ASBP Comparison
Compare TPST & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | ASBP |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 15.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | ASBP |
|---|---|---|
| Price | $2.71 | $2.16 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | 75.6K | ★ 1.2M |
| Earning Date | 11-05-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.40 | $0.05 |
| 52 Week High | $13.13 | $632.00 |
Technical Indicators
Market Signals| Indicator | TPST | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 95.30 |
| Support Level | $2.40 | $0.05 |
| Resistance Level | $3.03 | $0.10 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.11 | 0.13 |
| Stochastic Oscillator | 51.00 | 95.90 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.